I had read countless legal documents about the world's bestselling drug. But it took a trip to Latin America to see how scarcity shapes life and death decisions.

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...

The biotechnology and drug manufacturing market continues to give investors a hit-and-miss. Bears are betting heavily against Hims and Hers (HIMS), holding a short interest of 28.31%. On May 21, Hims ...

US biotech Inhibrx Biosciences (Nasdaq: INBX) has reported encouraging mid-stage data for its OX40 agonist INBRX-106, showing ...

Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades ...

Fresh tax cuts, an instant $1,000 tax reduction and cheaper medicines: here's what the federal government's latest budget means for Australians.

This is the first commercial path to products made in space,” says Michael Reilly, Varda’s chief strategy officer. The ...

Hims launched generic Semaglutide in Canada, opening a lower-cost alternative to Novo Nordisk’s Ozempic and Wegovy. ・Health Canada recently approved the first generic semaglutide products in the G7.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy generics that could cost as little as $15 a month.

Merck’s MRK stock has declined 7.3% in the past month despite announcing a solid first-quarter 2026 report on April 30. Merck beat estimates for both earnings and sales. Total r ...